Neurogene Inc. (NGNE) short interest & options flow
NASDAQNeurogene Inc. heads into the week after its August 12 earnings release with analyst targets scattered across a wide range and short interest entrenched near a fifth of the free float. The analyst reaction to earnings landed within hours of the results. Canaccord Genuity's Whitney Ijem kept her Buy rating but trimmed the target from $180 to $166. Guggenheim moved the other way…
- Market cap
- $520M
- Next earnings
- 10 Nov 2026
Key data as of 10 Nov 2026

NGNE news and analysis
RSSNo long-form analysis yet for NGNE. Pulse alerts and the live data picture are available on ORTEX.
Open NGNE on ORTEX →Want the live picture for NGNE?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NGNE — free to start on ORTEX.
Sign up for free →Open NGNE on ORTEX